Highlights
About
Enhancing Proteins to Create New Treatments for Diabetes
iProTide seeks to enhance protein-based drug discovery through innovations related to the physical, chemical, and biological properties of amino acids. Initially, the company plans to focus on peptides and proteins associated with obesity and diabetes. There is an unmet need for proteins/peptides that are efficacious in very small doses (high bio-availability), stable, and specific. iProTides technology is based on chemical modifications made within the backbone of proteins and amino acids without altering the side chain. These chemical modifications will potentially give rise to enhanced proteins with better stability and with distinct folding properties. They could also enhance the activity and specificity of these proteins/peptides. The changes will be tested for their potential in enhancing the efficiency of known peptide-based therapeutics, and mayenable the re-use of peptides/proteins that failed clinical trials due to PK/PD, toxicity, and efficiency issues.
Identity
| Name | iProTide |
|---|---|
| Slug | iprotide |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6uzbkLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2016 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Modi'in-Maccabim-Re'ut |
| HQ address | Yahalom Street 33/3, Modi'in-Maccabim-Re'ut, Israel |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}